A Phase 4 interventional study of Acoramidis in Transthyretin-type Cardiac Amyloidosis, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 16 sites in Japan. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Amyloidosis with a site in Japan — 10 open to participants now, 12 under way, 7 of them phase 3. Amyloidosis · Japan.
Among the 24 studies in Amyloidosis with a site in Japan, this one is the 15th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 4, reaches primary completion later than 7 of the 11 other live ones, and was the 24th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →10 of the 24 studies in Amyloidosis with a site in Japan are open now. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in Japan, United States, Argentina and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in Japan, United States, Germany
Ages 18+
Alnylam Pharmaceuticals · Sites in Japan, United States, Argentina and 33 more countries
Ages 18–85
Eidos Therapeutics, a BridgeBio company · Sites in Japan, United States, Argentina and 21 more countries
Ages 18–75
AbbVie · Sites in Japan, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 16 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 360 across the 21 interventional studies, 6,718 across the 3 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
AstraZeneca has 8 studies filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyloidosis with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05652335Janssen Research & Development, LLCA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | 2027-04-19 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Amyloidosis with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Naive participants must meet the following requirements:
Confirmed diagnosis of ATTR-CM (wild type or mutant) by one of the following diagnostic methods
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 800 mg of acoramidis twice daily for 18 months.
Drug: Acoramidis
Participants will receive acoramidis tablets orally.
Also known as: acoramidis hydrochloride Byontra
Disease Progression Rate as Measured by N-terminal pro-brain-type Natriuretic Peptide (NT-proBNP) and/or Outpatient Diuretic Intensification (ODI)
Time frame: Baseline through 12 months
Disease Progression Rate as Measured by NT-proBNP and/or High-sensitivity Cardiac Troponin T (hs-CTnT)
Time frame: Baseline through 12 months
Change from Baseline in Serum Transthyretin (TTR)
Time frame: Baseline, 28 days
Number of Participants with a 30% Change from Baseline in NT-proBNP
Time frame: Baseline, 12 months and 18 months
Change from Baseline in hs-CTnT
Time frame: Baseline, 12 months and 18 months
Change from Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ-12) Overall Summary Score
Time frame: Baseline, 12 months and 18 months
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline, 12 months and 18 months
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acoramidis
Alexion Pharmaceuticals, Inc. →